Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Clin Oncol
Egile Nagusiak: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2021
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://ncbi.nlm.nih.gov/pubmed/33282288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2175
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak